Modeling HIV vaccine trials of the future.
Models of implementation of known-effective interventions for HIV prevention indicate that an efficacious vaccine to prevent HIV infection would be critical for controlling the HIV pandemic. Key issues in the design of future HIV vaccine trials are: first, how to develop reliable immunological correlates of vaccine efficacy, second, how to down-select candidate vaccine regimens into efficacy trials, and third, how to learn about vaccine efficacy in the context of the evolving HIV prevention landscape.



Whereas in the past phase-I/-II HIV vaccine trials have addressed the first and second points using a small set of immunological assays and readouts, recently they have used a battery of assays with highly multivariate readouts. In addition, systems vaccinology studies of other pathogens measuring PBMC transcriptomics and other immunological features pre- and postfirst vaccination are demonstrating value, for example, providing discoveries that preimmunization and early postimmunization cell population markers can predict the influenza-specific antibody titer that is a correlate of vaccine protection. The HIV prevention landscape continues to evolve, and the design and analysis of vaccine trials is evolving alongside, to accommodate increasingly dynamic and regional standards of HIV prevention.



Development of interpretable and robust functional assays, in addition to the associated bioinformatics and statistical analytic tools, is needed to improve the assessment of correlates of protection in efficacy trials and the down-selection of candidate vaccine regimens into efficacy trials. Moreover, high-priority trials should integrate systems vaccinology, including the analysis of prevaccination and early postvaccination markers.
aVaccine and Infectious Disease and Public Health Science Divisions, Fred Hutchinson Cancer Research CenterbDepartment of Biostatistics, University of Washington, Seattle, Washington, USA*Peter B. Gilbert, Ying Huang, and Holly E. Janes contributed equally to the writing of this article.
Peter B
PB
Gilbert
Ying
Y
Huang
Holly E
HE
Janes
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000302:isolation & purification; D015415:Biomarkers; D002986:Clinical Trials as Topic; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D015233:Models, Statistical; D016896:Treatment Outcome
D016915:AIDS Vaccines; D015415:Biomarkers
AIDS. 2000 Oct 20;14(15):2361-70
11089625
J Infect Dis. 2006 Dec 15;194(12):1661-71
17109337
Biometrics. 2006 Dec;62(4):1161-9
17156291
Biometrics. 2008 Dec;64(4):1146-54
18363776
Nat Immunol. 2009 Jan;10(1):116-125
19029902
J Exp Med. 2008 Dec 22;205(13):3119-31
19047440
Biometrics. 2009 Dec;65(4):1223-32
19397589
Nat Rev Immunol. 2009 Oct;9(10):741-7
19763148
N Engl J Med. 2009 Dec 3;361(23):2209-20
19843557
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
20463105
AIDS Res Hum Retroviruses. 2011 Jun;27(6):669-80
21043994
N Engl J Med. 2010 Dec 30;363(27):2587-99
21091279
J Infect Dis. 2011 Apr 1;203(7):921-9
21357945
Biometrics. 2011 Dec;67(4):1442-51
21517791
Nat Immunol. 2011 Jul 10;12(8):786-95
21743478
PLoS One. 2011;6(8):e21225
21857901
Clin Infect Dis. 2012 Jun;54(11):1615-7
22437237
N Engl J Med. 2012 Apr 5;366(14):1275-86
22475592
Stat Med. 2012 Nov 10;31(25):2973-84
22711298
N Engl J Med. 2012 Aug 2;367(5):399-410
22784037
N Engl J Med. 2012 Aug 2;367(5):423-34
22784038
J Infect Dis. 2012 Oct 1;206(7):993-1001
22829639
AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90
22935078
J Infect Dis. 2013 Jan 15;207(2):248-56
23125443
Stat Commun Infect Dis. 2011 Oct;3(1):null
23181167
Am J Epidemiol. 2013 Feb 1;177(3):256-63
23302152
Clin Infect Dis. 2013 May;56(10):1458-65
23386629
Biometrics. 2013 Jun;69(2):301-9
23409839
AIDS Res Hum Retroviruses. 2013 Nov;29(11):1513-23
23597282
Immunity. 2013 Apr 18;38(4):831-44
23601689
Semin Immunol. 2013 Oct 31;25(3):209-18
23796714
N Engl J Med. 2013 Nov 28;369(22):2083-92
24099601
PLoS One. 2014 Feb 04;9(2):e87572
24504509
Cell. 2014 Apr 10;157(2):499-513
24725414
J Infect Dis. 2014 Nov 15;210(10):1573-81
24823623
AIDS Res Hum Retroviruses. 2014 Nov;30(11):1017-22
24857015
Vaccines (Basel). 2014 Mar;2(1):15-35
24932411
Lancet Infect Dis. 2014 Sep;14(9):820-9
25065857
Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12300-6
25136102
J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):324-31
25157647
Annu Rev Med. 2015;66:423-37
25341006
Stat Med. 2015 Feb 10;34(3):381-95
25352131
PLoS One. 2015 Jan 08;10(1):e0115528
25569838
Stat Med. 2015 May 10;34(10):1747-60
25628249
J Infect Dis. 2015 Sep 1;212(5):754-9
25712973
Clin Trials. 2015 Aug;12(4):394-402
25851992
Vaccine. 2015 Sep 29;33(40):5294-301
25858860
Vaccine. 2015 Sep 29;33(40):5262-70
25957070
Nat Biotechnol. 2015 Jun;33(6):610-6
26006008
AIDS Res Hum Retroviruses. 2015 Nov;31(11):1060-76
26107771
Trends Immunol. 2015 Aug;36(8):479-93
26187853
Lancet. 2016 Jan 2;387(10013):53-60
26364263
Curr Opin HIV AIDS. 2016 Jan;11(1):18-26
26417954
Am J Epidemiol. 2015 Nov 15;182(10):848-56
26487343
Sci Transl Med. 2015 Oct 21;7(310):310rv7
26491081
Cell. 2015 Nov 5;163(4):988-98
26544943
J Causal Inference. 2015 Sep 1;3(2):157-175
26722639
Curr Opin Virol. 2016 Apr;17:57-65
26827165
N Engl J Med. 2016 Dec;375(22):2121-2132
26900902
Glob Public Health. 2018 May;13(5):626-641
27194404
Epidemiol Methods. 2016 Dec;5(1):93-112
28154793